Gliclazide Mainly Affects Insulin Secretion in Second Phase of Type 2 Diabetes Mellitus

We studied the effect of the acute administration of gliclazide at 160 mg on insulin release during hyperglycaemic clamps in 12 type 2 diabetes patients, age 50 ± 9.0 years, diabetes duration 5.5 ± 4.8 years, fasting blood glucose 9.6 ± 2.1 mmol/L (means ± SD). After a 210 min of hyperinsulinaemic euglycaemic clamp (blood glucose 4.6 ± 0.14 mmol/L), gliclazide or placebo (randomised, double-blind, cross-over) was administered; 60 minutes later, a hyperglycaemic clamp (4 hr) at 8 mmol/L was started. Plasma C-peptide levels increased significantly after the administration of gliclazide (increment 0.17 ± 0.15 vs. 0.04 ± 0.07 nmol/L, p = 0.024) before the clamp. After the start of the hyperglycaemic clamp, the areas under the curve (AUC) for insulin and C-peptide did not differ from 0 - 10 min (first phase) with gliclazide. However, second-phase insulin release (30 - 240 min) was markedly enhanced by gliclazide. AUC plasma insulin (30 to 240 min) was statistically significantly higher after gliclazide (12.3 ± 13.9 vs. - 0.56 ± 9.4 nmol/L × 210 min, p = 0.022); similarly, AUC plasma C-peptide (30 to 240 min) was also higher: 128 ± 62 vs. 63 ± 50 nmol/L × 210 min, p = 0.002). In conclusion, in long-standing type 2 diabetes the acute administration of gliclazide significantly enhances second phase insulin release at a moderately elevated blood glucose level. In contrast to previous findings in mildly diabetic subjects, these 12 type 2 diabetes patients who had an inconsiderable first phase insulin release on the placebo day, only showed an insignificant increase in first phase with gliclazide.

Gliclazide - Insulin Secretion - Type 2 Diabetes

References

• 1 Yki-Jarvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus.  Lancet. 1994;  343 91-95
• 2 Van Haeften T W, Boonstra E, Veneman T F, Gerich J E, Van der Veen E A. Dose-response characteristics for glucose-stimulated insulin release in man and the assessment of influence of glucose on arginine stimulated insulin release.  Metabolism. 1990;  39 1292-1299
• 3 Van Haeften T W, Van Maarschalkerweerd W WA, Gerich J E, Van der Veen E A. Decreased insulin secretory capacity and normal pancreatic B-cell glucose sensitivity in non-obese patients with NIDDM.  Eur J Clin Invest. 1991;  21 168-174
• 4 Wolffenbuttel B HR, Van Haeften T W. Non-insulin-dependent diabetes mellitus: defects in insulin secretion.  Eur J Clin Invest. 1993;  23 69-79
• 5 Gerich J E. Oral hypoglycemic agents.  N Engl J Med. 1989;  321 1231-1245
• 6 Groop L C. Sulfonylureas in NIDDM.  Diabetes Care. 1992;  15 737-754
• 7 Wolffenbuttel B HR, Van Haeften T W. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).  Drugs. 1995;  50 263-288
• 8 Van Haeften T W, Veneman T F, Gerich J E, Van der Veen E A. Influence of gliclazide on glucose-stimulated insulin release in man.  Metabolism. 1991;  40 751-755
• 9 Hosker J P, Rudenski A S, Burnett M A, Matthews D R, Turner R C. Similar reductions of first and second phase-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.  Metabolism. 1989;  38 767-772
• 10 Liu D, Moberg E, Kollind M, Lins P, Adamson U, Macdonald I A. Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycemia and hypoglycemia.  Diabetologia. 1992;  35 287-290
• 11 Wahren J, Johansson B L. Ernst-Friedich-Pfeiffer Memorial Lecture. New aspects of C-peptide physiology.  Horm Metab Res. 1998;  30 A2-A5
• 12 Metz S A, Halter J B, Robertson R P. Paradoxical inhibition of insulin secretion by glucose in human diabetes mellitus.  J Clin Endocrinol Metab. 1979;  48 827-835
• 13 Nesher R, Cerasi E. Biphasic insulin release as the expression of combined inhibitory and potentiating effects of glucose.  Endocrinology. 1987;  121 1017-1024
• 14 Ligtenberg J JM, Sluiter W J, Reitsma W D, Van Haeften T W. Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man.  Eur J Clin Invest. 1997;  27 685-689
• 15 Johnson A B, Argyraki M, Thow J C, Jones I R, Broughton D, Miller M, Taylor R. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.  Diabetic Medicine. 1991;  8 243-253
• 16 Widstrom A, Cerasi E. On the action of tolbutamide in normal man. Modulation of glucose-induced insulin release by tolbutamide.  Acta Endocrinol. 1973;  72 519-531
• 17 Groop L C, Melander A, Groop P, Ratheiser K, Simonson D C, DeFronzo R A. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects.  Diabetes. 1987;  36 1320-1328
• 18 Hosker J P, Burnett M A, Davies E G, Harris E A, Turner R C. Sulfonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.  Diabetologia. 1985;  28 809-814
• 19 Clark H E, Matthews D R. The effect of glimepiride on pancreatic β cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in NIDDM.  Horm Metab Res. 1996;  28 445-450
• 20 Ashcroft F M. Mechanisms of the glycaemic effects of sulfonylureas.  Horm Metab. Res1996;  28 456-463
• 21 Eliasson L, Renstroom E, Ammala C, Berggren P O, Bertorello A M, Bokvist K, Chibalin A, Deeney J T, Flatt P R, Gabel J, Gromada J, Larsson O, Lindstrom P, Rhodes C J, Rorsman P. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic ß cells.  Science. 1996;  276 813-815